Processing method of alisma herb paste for treating lymphedema and application thereof

CN122912043APending Publication Date: 2026-10-16ABAGA BANNER MONGOLIAN MEDICAL HOSPITAL
2 Cites 0 Cited by

Patent Information

Application Number
CN202611411357.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-11
Publication Date
2026-10-16

AI Technical Summary

Technical Problem

[0008]现有关于泡囊草“消肿”功效的应用主要针对疮痈肿毒等炎症性肿胀,而淋巴水肿的病理核心是淋巴管回流障碍导致的高蛋白淋巴液淤积,与普通炎症性水肿的病理机制存在本质差异

Benefits of technology

本发明将水提、酶解与发酵技术系统性整合应用于泡囊草的炮制工艺中,形成了一条传统减毒—现代增效的完整工艺流程。通过精确控制牛奶浸泡比例与低温干燥条件,配合8~10倍量水分梯度煎煮,确保有效成分充分溶出;进而采用特定配比的纤维素酶和果胶酶在温和条件下定向酶解,破坏植物细胞壁屏障,显著提高山莨菪碱、黄酮类等活性成分的释放率;再以枯草芽孢杆菌、酿酒酵母和乳酸菌组成的复合发酵剂进行控温发酵,利用多菌种协同作用实现复杂成分的生物转化,在进一步降低残余毒性的同时增强原有药理活性。各步骤工艺参数明确、可控,具有良好的重现性和工业化生产前景。本发明制得的泡囊草膏安全性更高、有效成分含量更丰富、药效更显著,为淋巴水肿这一临床难治性疾病提供了新的有效治疗途径,具有重要的临床应用价值和社会意义。

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The application provides a processing method of Kuancao paste for treating lymphedema and application thereof, and belongs to the technical field of medicine preparation. The application systematically integrates water extraction, enzymolysis and fermentation technology in the processing technology of Kuancao, and forms a complete process flow of traditional attenuation-modern synergism. By precisely controlling the milk soaking ratio and low-temperature drying conditions, and cooperating with 8-10 times amount of water gradient decoction, the effective components are ensured to be fully dissolved; then specific proportion cellulase and pectinase are used for directional enzymolysis under mild conditions, the plant cell wall barrier is destroyed, and the release rate of active components such as anisodine and flavones is significantly improved; finally, the composite starter composed of bacillus subtilis, saccharomyces cerevisiae and lactic acid bacteria is used for temperature control fermentation, the multi-strain synergistic effect is used to realize the biological transformation of complex components, and the residual toxicity is further reduced while the original pharmacological activity is enhanced.
Need to check novelty before this filing date? Find Prior Art